Decera Clinical Education Oncology Podcast

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:Local therapy in the context of MBCChoice of therapy after progression on available standards of careChoice of trastuzumab deruxtecan and tucatinib based on patient presentationManaging patients with CNS metastasesManaging interstitial lung diseasePresenters:Thomas Bachelot, MD, PhDChair, Unicancer Breast Group - UCBGBreast Cancer UnitMedical Oncology Centre Léon BérardLyon, FranceAdam M. Brufsky, MD, PhDProfessor of Medicine Hematology/Oncology University of Pittsburgh School of MedicineAssociate Chief, Hematology-OncologyUniversity of Pittsburgh Cancer InstitutePittsburgh, PennsylvaniaCristina Saura, MD, PhDMedicine and Surgery/Medical OncologyUniversidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)Head, Breast Cancer ProgramMedical OncologyVall d’Hebron University HospitalBarcelona, SpainContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including associated downloadable slidesets:https://bit.ly/32A1HMb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:Treating beyond progression with immunotherapyManagement of patients with less common histologic subtypes of RCCPotential biomarkers for RCCAdverse event managementPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.Presenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:•           The impact of COVID-19 on CLL treatment decisions•           The use of anti-CD20 antibodies in combination with BTK inhibitors•           Considerations when recommending BTK inhibitors•           MRD testing in patients with CLL•           The potential impact of targeted therapies on when to start treatmentPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets: https://bit.ly/3hATX0L     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:Optimal testing for RET fusionsDNA NGS vs RNA NGSMolecular testing workflowsUsing new selective RET inhibitors to treat patients with RET fusion–positive NSCLCCommon toxicities with new selective RET inhibitorsInterdisciplinary communication between medical oncologists and pathologistsPresenters:Dara L. Aisner, MD, PhDAssociate ProfessorDepartment of PathologyDirector, Molecular PathologyUniversity of ColoradoAurora, ColoradoJoshua Bauml, MDAssistant Professor of MedicineDivision of Hematology/OncologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program, including associated downloadable slidesets:https://bit.ly/2Fsq9Wv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:Rechallenging patients with venetoclax and BTK inhibitors Mechanism by which BTK inhibitors may reduce infusion reactionsRisk of secondary malignancies with BTK inhibitionDifferent cytogenetic findings and adverse event riskPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:Optimal use of approved CAR T-cell therapies for lymphoma and ALLInvestigational CAR T-cell therapies for multiple myelomaManaging CAR T-cell therapy–related toxicitiesPresenters:Michael R. Bishop, MDProfessor of MedicineSection of Hematology/OncologyDirector, Cellular Therapy ProgramUniversity of ChicagoChicago, IllinoisDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief, Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsNoopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.Link to full program:https://bit.ly/3iyt5zQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:•           Treatment sequencing with IO and TKI therapies•           Optimizing dose for patients with preexisting toxicities•           Considerations for local control of metastatic sites •           Ongoing clinical trials Presenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial • Selecting therapy for a patient with lenalidomide-refractory disease at first relapse• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms• Key findings from the DREAMM2 trial on belantamab mafodotin• Monitoring and management strategies for ocular toxicity with belantamab mafodotinPresenters:Jesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainPaula Rodriguez-Otero, MD, PhDAssociate ProfessorConsultant in HematologyDepartment of Hematology, Clínica Universidad de NavarraUniversity of NavarraPamplona, SpainProf. Dr. med. Katja Weisel  Deputy DirectorII. Medical Clinic and PolyclinicDepartment of Oncology and HematologyDepartment of Pneumology and Bone Marrow TransplantationUniversity Medical Center  Hamburg-EppendorfHamburg, GermanyContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program, including associated downloadable slidesets: https://bit.ly/2QRqYuC  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.Presenters:Natalie S. Callander, MDProfessor of Medicine  Director, Myeloma Clinical Program  University of Wisconsin Carbone Cancer CenterMadison, WisconsinShaji Kumar, MDDepartment of HematologyMayo ClinicRochester, MinnesotaContent based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.Link to full program, including associated downloadable slidesets: https://bit.ly/3gT324y Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.